Management of antimicrobial use in the intensive care unit

Drugs

Volumn 72, Issue 4, 2012, Pages 447-470

  Álvarez Lerma, Francisco ^a   Grau, Santiago ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Acinetobacter infections; Amikacin; Aminoglycosides; Antimicrobial resistance; Aspergillosis; Azithromycin; Aztreonam; Beta lactams; Candidiasis; Carbapenems; Cefpirome; Ceftazidime; Ceftriaxone; Cephalosporins; Cilastatin; Ciprofloxacin; Colistimethate sodium; Colistin; Cotrimoxazole; Daptomycin; Doripenem; Doxycycline; Ertapenem; Fluoroquinolones; Fosfomycin; Gentamicin; Glycylcyclines; Gram negative infections; Healthcare expenditure; Imipenem; Intensive care units; Levofloxacin; Linezolid; Meropenem; Methicillin resistant Staphylococcus aureus infections; Metronidazole; Nosocomial pneumonia; Oxacillin; Pharmacokinetic pharmacodynamic relationships; Piperacillin; Pseudomonal infections; Quinupristindalfopristin; Rifampicin; Sepsis; Septic shock; Staphylococcal infections; Streptococcal infections; Sulbactamampicillin; Tazobactam; Teicoplanin; Telavancin; Tetracycline; Tigecycline; Vancomycin; Vancomycin resistant enterococcal infections; Vancomycin resistant Staphylococcus aureus infections

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFPIROME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; COLISTIN; COTRIMOXAZOLE; ECHINOCANDIN; FOSFOMYCIN; GLYCYLCYCLINE DERIVATIVE; IMIPENEM; LINCOSAMIDE; LINEZOLID; MACROLIDE; METRONIDAZOLE; MONOBACTAM DERIVATIVE; PENICILLIN G; POLYMYXIN; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; TIGECYCLINE; UNINDEXED DRUG; UREIDOPENICILLIN DERIVATIVE; VANCOMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ANTIBACTERIAL CYCLING; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERICIDAL ACTIVITY; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTINUOUS HEMOFILTRATION; CONTINUOUS INFUSION; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DISEASE COURSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MONITORING; DRUG TREATMENT FAILURE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; HYDROPHILICITY; INFECTION; INFECTION PREVENTION; INTENSIVE CARE; INTENSIVE CARE UNIT; LIPOPHILICITY; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PSEUDOMONAS AERUGINOSA; REVIEW; SEPSIS; SEPTIC SHOCK; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; TIME; UNSPECIFIED SIDE EFFECT; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84857252132     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11599520-000000000-00000     Document Type: Review

References (202)

1. Doyle JS, Buising KL, Thursky KA, et al. Epidemiology of infections acquired in intensive care units. Semin Respir Crit Care Med 2011; 32: 115-38
2. Meyer E, Schwab F, Jonas D, et al. Surveillance of antimicrobial use and antimicrobial resistance in intensive care units (SARI), 1: antimicrobial use in German intensive care units. Intensive Care Med 2004; 30: 1089-96 (Pubitemid 38833360)
3. Pea F, Viale P. Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections. Expert Rev Anti Infect Ther 2007; 5: 255-70 (Pubitemid 46681744)
4. Alvarez Lerma F, Palomar M, Grau S. Management of antimicrobial use in the intensive care unit. Drugs 2001; 61: 763-75 (Pubitemid 32507005)
5. Kollef MH. Hospital-acquired pneumonia and deescalation of antimicrobial treatment. Crit Care Med 2001; 29: 1473-5 (Pubitemid 32641815)
6. Antonelli M, Mercurio G, Di Nunno S, et al. De-escalation antimicrobial chemotherapy in critically III patients: pros and cons. J Chemother 2001; 13 Spec. No. 1 (1): 218-23 (Pubitemid 34183618)
7. McGowan Jr JE. Strategies for study of the role of cycling on antimicrobial use and resistance. Infect Control Hosp Epidemiol 2000; 21: S36-43
8. Kollef MH. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the Intensive Care Unit? Clin Infect Dis 2006; 43 Suppl. 2: S82-8 (Pubitemid 44267145)
9. Playford EG, Lipman J, Sorrell TC. Prophylaxis, empirical and preemptive treatment of invasive candidiasis. Curr Opin Crit Care 2010; 16: 470-4
10. Roberts JA. Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotechnol 2011; 12: 2070-9
11. Varghese JM, Roberts JA, Lipman J. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin 2011; 27: 19-34
12. Karageorgopoulos DE, Falagas ME. New antibiotics: optimal use in current clinical practice. Int J Antimicrob Agents 2009; 34 Suppl. 4: S55-62
13. Sociedad Españ ola de Medicina Intensiva. Grupo de Trabajo de Enfermedades Infecciosas (SEMICYUC-GTEI). Estudio Nacional de Vigilancia de Infecció n Nosocomial en UCI (ENVIN-UCI). Informes de los añ os 2001-2010 [online]. Available from URL: http://hws.vhebron.net/envin-helics/ [Accessed 2011 Jul 24]
14. Vincent JL, Rello J, Marshall J, et al., for the EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302 (21): 2323-9
15. Sociedad Española de Medicina Preventiva Salud Pú blica e Higiene. Informe EPINE 2010 [online]. Available from URL: http://www.sempsph. com/sempsph/attachments/327-Informe%20EPINE-2010%20ESPAN~A.pdf [Accessed 2011 Jul 24]
16. Alvarez Lerma F, Sierra Camerino R, Alvarez Rocha L, et al. Politica de antibió tiocs en UCI. Med Intensiva 2010; 34: 600-8
17. Alvarez-Lerma F. Modification of empiric treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22: 387-94 (Pubitemid 26174308)
18. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilatorassociated pneumonia. Chest 1997; 111: 676-85 (Pubitemid 27132946)
19. Leibovici L, Shraga I, Drucker M, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 224: 379-86 (Pubitemid 28513125)
20. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-74 (Pubitemid 29083057)
21. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient in the ICU setting. Chest 2000; 118: 146-55 (Pubitemid 30485502)
22. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262-8 (Pubitemid 34754172)
23. Zaragoza R, Artero A, Camarena JJ, et al. The influence of inadequate empirical antrimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003; 9: 412-8 (Pubitemid 36758130)
24. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44: 1009-34 (Pubitemid 41356389)
25. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37: 840-51
26. Schentag JJ. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy an avoid resistance. J Chemother 1999; 11: 426-39 (Pubitemid 30029540)
27. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associared with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42: 521-7 (Pubitemid 28114802)
28. Craig WA. Pharmacokinetic/phamacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10
29. Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010; 375: 248-51
30. McKenzie C. Antibiotic dosing in critical illness. J Antimicrob Chemother 2011; 66 Suppl. 2: 25-31
31. Dorman T, Swoboda S, Zarfeshenfard F, et al. Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Research Group. Surgery 1998; 124: 73-8 (Pubitemid 28354688)
32. Taccone FS, Laterre PF, Dugernier T, et al. Insufficient b-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010; 14: R126
33. Rea RS, Capitano B, Bies R, et al. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008; 30: 674-81
34. Brunner M, Pernerstorfer T, Mayer BX, et al. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med 2000; 28: 1754-9 (Pubitemid 30428724)
35. Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001; 29: 385-91 (Pubitemid 32171786)
36. Joukhadar C, Klein N, Mayer BX, et al. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med 2002; 30: 1478-82 (Pubitemid 34756228)
37. Gó mez CM, Cordingly JJ, Palazzo MG. Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 1999; 43: 1798-802 (Pubitemid 29331273)
38. Hanes SD, Wood GC, Herring V, et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000; 179: 436-40
39. McKindley DS, Boucher BA, Hess MM, et al. Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia. Pharmacotherapy 1996; 16: 924-31 (Pubitemid 26322195)
40. Botha FJ, van der Bijl P, Seifart HI, et al. Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. Intensive Care Med 1996; 22: 443-6 (Pubitemid 26174317)
41. Ronchera-Oms CL, Tormo C, Ordová s JP, et al. Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition. J Clin Pharm Ther 1995; 20: 253-8
42. Hary L, Andrejak M, Leleu S, et al. The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites. Eur J Clin Pharmacol 1989; 36: 613-6 (Pubitemid 19175874)
43. Hary L, Smail A, Ducroix JP, et al. Pharmacokinetics and ascitic fluid penetration of piperacillin in cirrhosis. Fundam Clin Pharmacol 1991; 5: 789-95
44. SAFE Study Investigators. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ 2006; 333: 1044
45. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007; 27: 1081-91
46. Udy AA, Roberts JA, Lipman J. Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol 2011; 7: 539-43
47. Blanchet B, Jullien V, Vinsonneau C, et al. Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet 2008; 47: 635-54
48. Dailly E, Le Floch R, Deslandes G, et al. Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients. Int J Antimicrob Agents 2008; 31: 537-9
49. Conil JM, Georges B, Lavit M, et al. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation. Br J Clin Pharmacol 2007; 64: 27-35 (Pubitemid 46934422)
50. Friedrich LV, White RL, Kays MB, et al. Aztreonam pharmacokinetics in burn patients. Antimicrob Agents Chemother 1991; 35: 57-61
51. Conil JM, Georges B, Lavit M, et al. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance. Int J Clin Pharmacol Ther 2007; 45: 529-38 (Pubitemid 47527452)
52. Doh K, Woo H, Hur J, et al. Population pharmacokinetics of meropenem in burn patients. J Antimicrob Chemother 2010; 65: 2428-35
53. Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999; 43: 2559-61 (Pubitemid 29471248)
54. Lipman J, Scribante J, Gous AG, et al. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. Antimicrob Agents Chemother 1998; 42: 2235-9 (Pubitemid 28420356)
55. Pea F, Di Qual E, Cusenza A, et al. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet 2003; 42: 589-98 (Pubitemid 36801876)
56. Pea F, Porreca L, Baraldo M, et al. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000; 45: 329-35 (Pubitemid 30139241)
57. Ferná ndez de Gatta MM, Fruns I, Herná ndez JM, et al. Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies. Clin Pharm 1993; 12: 515-20 (Pubitemid 23178609)
58. Lortholary O, Tod M, Rizzo N, et al. Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Antimicrob Agents Chemother 1996; 40: 1242-7 (Pubitemid 26136041)
59. Romano S, Fdez de Gatta MM, Calvo MV, et al. Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother 1999; 44: 235-42 (Pubitemid 29389287)
60. Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29: 562-77
61. Pea F, Viale P, Pavan F, et al. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 2007; 46: 997-1038 (Pubitemid 350136909)
62. Taccone FS, de Backer D, Laterre PF, et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2011; 37: 531-5
63. Seyler L, Cotton F, Taccone FS, et al. Recommended b-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011; 15 (3): R137
64. A ́ lvarez Lerma F, Palomar Martinez M. Antibiotic policy in critically ill patients. In: Gullo A, Besso J, Lumb PD, editors. WFSICCM. World Federations of Societies of Intensive and Critical Care Medicine. Intensive and critical care medicine. Milan: Springer-Verlag Italia, 2009: 237-49
65. MacAdam H, Zaoutis TE, Gasink LB, et al. Investigating the association between antibiotic use and antibiotic resistance: impact of different methods of categorising prior antibiotic use. Int J Antimicrob Agents 2006; 28: 325-32 (Pubitemid 44402991)
66. Kaki R, Elligsen M, Walker S, et al. Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother 2011; 66: 1223-30
67. Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004; 32: 2183-90 (Pubitemid 39491796)
68. A ́ lvarez-Lerma F, Alvarez B, Luque P, et al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care 2006; 10: R78
69. Leone M, Garcin F, Bouvenot J, et al. Ventilatorassociated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med 2007; 35: 379-85 (Pubitemid 46148525)
70. Giantsou E, Liratzopoulos N, Efraimidou E, et al. Deescalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med 2007; 33: 1533-40 (Pubitemid 47312455)
71. De Waele JJ, Ravyts M, Depuydt P, et al. De-escalation after empirical meropenem treatment in the intensive care unit: fiction or reality? J Crit Care 2010; 25: 641-6
72. Eachempati SR, Hydo LJ, Shou J, et al. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma 2009; 66: 1343-8
73. Leone M, Bourgoin A, Cambon S, et al. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med 2003; 31: 462-7 (Pubitemid 36232941)
74. Joung MK, Lee JA, Moon SY, et al. Impact of deescalation therapy on clinical outcomes for intensive care unit-acquired pneumonia. Crit Care 2011; 15 (2): R79
75. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416
76. Gerding DN, Larson TA, Hughes RA, et al. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother 1991; 35: 1284-90
77. Kollef MH, Vlasnik J, Sharpless L, et al. Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156: 1040-8
78. Gruson D, Hibert G, Vargas F, et al. Rotation and restricted use of antibiotics in a medical intensive care unit: impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Am J Respir Crit Care Med 2000; 162: 837-43
79. Hughes MG, Evans HL, Chong TW, et al. Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infections on the non-intensive care unit ward. Crit Care Med 2004; 32: 53-60 (Pubitemid 38125562)
80. Merz LR, Warren DK, Kollef MH, et al. Effects of an antibiotic cycling program on antibiotic prescribing practices in an intensive care unit. Antimicrob Agents Chemother 2004; 48: 2861-5 (Pubitemid 38989147)
81. Warren DK, Hill HA, Merz LR, et al. Cycling empirical antimicrobial agents to prevent emergence of antimicrobial resistant Gram-negative bacteria among intensive care unit patients. Crit Care Med 2004; 32: 2450-6 (Pubitemid 39648227)
82. Mart́nez JA, Nicolá s JM, Marco F, et al. Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units. Crit Care Med 2006; 34: 329-36 (Pubitemid 43145609)
83. Sandiumenge A, Diaz E, Rodŕguez A, et al. Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother 2006; 57: 1197-204 (Pubitemid 44644425)
84. Brown E, Nathwani D. Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. J Antimicrob Chemother 2005; 55: 6-9 (Pubitemid 40192608)
85. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005; 18: 638-56 (Pubitemid 41504509)
86. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-50 (Pubitemid 41534660)
87. Tan BH, Chlebicka NL, Low JG, et al. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review. Transpl Infect Dis 2008; 10: 325-32
88. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006; 25: 419-25 (Pubitemid 44078593)
89. Pittet D, Monod M, Suter PM, et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-8 (Pubitemid 24376373)
90. Leó n C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system (Candida score) for preemptive antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34: 730-7
91. Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26: 271-6 (Pubitemid 46572022)
92. Hyatt JM, Schentag JJ. Potential role of pharmacokinetics, pharmacodynamics, and computerized databases in controlling bacterial resistance. Infect Control Hosp Epidemiol 2000; 21 Suppl. 1: S18-21
93. Schentag JJ. Antimicrobial management strategies for gram-positive bacterial resistance in the intensive care unit. Crit Care Med 2001; 29 Suppl. 4: S100-7
94. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients. Clin Pharmacokinet 2005; 44: 1009-34
95. Gillespie EL, Kuti JL, Nicolau DP. When 'S' does not mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infection. Conn Med 2005; 69: 203-10 (Pubitemid 40586359)
96. Soy D, Torres A. Antibacterial dosage in intensive-care unit patients based on pharmacokinetic/pharmacodynamic principles. Curr Opin Crit Care 2006; 12: 477-82 (Pubitemid 44341716)
97. Kuti JL, Nicolau DP. Making the most of surveillance studies: summary of the OPTAMA Program. Diagn Microbiol Infect Dis 2005; 53: 281-7 (Pubitemid 41796899)
98. Grau S, Alvarez-Lerma F, Doḿnguez-Gil A. Pharmacokinetic/ pharmacodynamic indices: are we ready to use them in daily practice? Expert Rev Anti Infect Ther 2007; 5: 913-6 (Pubitemid 350303021)
99. Preston SL. The importance of appropriate antimicrobial dosing: pharmacokinetic and pharmacodynamic considerations. Ann Pharmacother 2004; 38 (9 Suppl.): S14-8 (Pubitemid 39096696)
100. Craig WA. Pharmacodynamics of antimicrobials: general concepts and applications. In: Nightingale CH, Ambrose PG, Drusano GL, et al., editors. Antimicrobial pharmacodynamics in theory and clinical practice. New York: Informa Healthcare, 2007: 1-19
101. Taccone FS, Hites M, Beumier M, et al. Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock. Curr Infect Dis Resp 2011; 13: 406-15
102. Kim M-K, Nicolau DP. Aminoglycosides. In: Nightingale CH, Ambrose PG, Drusano GL, et al., editors. Antimicrobial pharmacodynamics in theory and clinical practice. New York: Informa Healthcare, 2007: 147-75
103. Layeux B, Taccone FWS, Fagnould D, et al. Amikacin monotherapy for sepsis by panresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54: 49-39-41
104. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-81 (Pubitemid 23141323)
105. Conil JM, Georges B, Lussy A, et al. Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. Int J Antimicrob Agents 2008; 32: 505-10
106. Khachman D, Conil JM, Georges B, et al. Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations. J Antimicrob Chemother 2011; 66: 1798-809
107. Sprandel KA, Drusano GL, Hecht DW, et al. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. Diagn Microbiol Infect Dis 2006; 55: 303-9 (Pubitemid 44128733)
108. Luque S, Grau S, Berenguer N, et al. Shedding light on the use of colistin: still gaps to be filled. Enf Infecc Microbiol Clin 2011; 29: 287-96
109. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically-ill patients from a multi-center study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94
110. Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of X-lactam antibiotics. Crit Care Med 2009; 37: 2071-8
111. Roberts JA, Ulldemolins M, Roberts MS, et al. Therapeutic drug monitoring of X-lactams in critically ill patients. Int J Antimicrob Agents 2010; 36: 332-9
112. Roberts JA, Kirkpatrick CMJ, Roberts MS, et al. Firstdose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010; 35: 156-63
113. Joukhadar C, Klein N, Dittrich P, et al. Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother 2003; 51: 1247-52 (Pubitemid 36622081)
114. Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/ pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008; 31: 122-9
115. Pea F, Furlanut M, Cojutti P, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 2010; 54: 4605-10
116. Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 2011; 66 Suppl. 4: 7-15
117. Rubinstein E, Vaughan D. Tigecycline. A novel glycylcycline. Drugs 2005; 65: 1317-36
118. Bhavnani SM, Rubino CM, Ambrose PG, et al. Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections. Antimicrob Agents Chemother 2010; 54: 1207-12
119. Moise-Broder PA, Forrest A, Birmingham C, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925-42 (Pubitemid 39447034)
120. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Cociety of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98
121. Ferná ndez de Gata MM, Revilla N, et al. Pharmacokinetic/ pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2007; 33: 279-85 (Pubitemid 46221233)
122. Roberts JA, Lipman J, Blot S, et al. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care 2008; 33: 1983-7
123. Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 2009; 53: 1863-7
124. Roberts JA, Taccone FS, Udy AA, et al. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 2011; 55: 2704-9
125. Edwards JR, Peterson KD, Yi Mu Y, et al. National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. Am J Infect Control 2009; 37: 783-805
126. Sociedad Españ ola de Medicina Intensiva. Grupo de Trabajo de Enfermedades Infecciosas (SEMICYUC-GTEI). Estudio Nacional de Vigilancia de Infecció n Nosocomial en UCI (ENVIN-UCI). Informes de los añ os 2001-2010 [online]. Available from URL: http://hws.vhebron.net/envin-helics/ [Accessed 2011 Jul 24]
127. Hidron AI, Edwards JR, Patel J, et al., National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29: 996-1011.
128. European Centre for Disease Prevention and Control. European Medicines Agency (ECDC/EMEA). Joint Technical report 2009. The bacterial challenge: time to react. EMEA doc. ref. EMEA/576176/2009. Consulta libre en la web [online]. Available from URL: http://www.ecdc.europa.eu/en/publications/Publications/0909- TER-The-Bacterial-Challenge-Time-to-React.pdf [Accessed 2011 Jul 24]
129. Sievert DM, Rudrik JT, Patel JB, et al. Vancomycinresistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008; 46: 668-74 (Pubitemid 351321548)
130. Soriano A, Marco F, Mart́nez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200 (Pubitemid 351269157)
131. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009; 29: 1275-9
132. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44 (Pubitemid 44631403)
133. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30: 388-94 (Pubitemid 38375611)
134. Kunkel M, Chastre JE, Kollef M, et al. Linezolid vs vancomycin in the treatment of nosocomial pneumonia proven due to methicillin-resistant Staphylococcus aureus [abstract no. 5047]. 48th Infectious Disease Society of America Annual Meeting; 2010 Oct 21-24; Vancouver (BC)
135. Fowler Jr VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.NEngl J Med 2006; 355: 653-65
136. Alvarez-Lerma F, Grau S, Gracia-Arnillas MP. Grampositive cocci infections in intensive care: guide to antibacterial selection. Drugs 2006; 66: 751-68 (Pubitemid 43765223)
137. Mensa J, Barberán J, Llinares P, et al. Recomendaciones para el tratamiento de las infecciones causadas por Staphylococcus aureus resistentes a meticilina. Rev Esp Quimioter 2008; 21: 234-58
138. Gudiol F, Aguado JM, Pascual A, et al. Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Españ ola de Enfermedades Infecciosas y Microbioloǵa Cĺnica. Enferm Infecc Microbiol Clin 2009; 27: 105-15
139. Liu C, Bayer A, Cosgrove SE, et al., Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: 18-55
140. van Hal SJ, Paterson DL. Systematic review and metaanalysis of the significance of heterogeneous vancomycinintermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55: 405-10
141. Twele L, Moyen E, Zhang K, et al. Methicillin-resistant Staphylococcus aureus endocarditis and de novo development of daptomycin resistance during therapy. Can J Infect Dis MedMicrobiol 2010; 21: 89-93
142. Sánchez Garća M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 303: 2260-4
143. Leonard SN, Szeto YG, Zolotarev M, et al. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA). Int J Antimicrob Agents 2011; 37: 558-61
144. Rubinstein E, Lalani T, Corey GR, et al., ATTAIN Study Group. Telavancin versus vancomycin for hospitalacquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011; 52: 31-40
145. Mart́nez JA, Ruthazer R, Hansjosten K, et al. Role of environmental contamination as a risk factor for acquisition of vancomycin-resistant enterococci in patients treated in a medical intensive care unit. Arch Intern Med 2003; 163: 1905-12 (Pubitemid 37082702)
146. Se YB, Chun HJ, Yi HJ, et al. Incidence and risk factors of infection caused by vancomycin-resistant enterococcus colonization in neurosurgical
147. Braun J S, Fica C A, Andrighetti B D, et al. Risk factors associated to vancomycin-resistant enterococccus colonization in the Army Hospital in Santiago [in Spanish]. Rev Chilena Infectol 2009; 26: 374-5
148. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004; 50: 59-69 (Pubitemid 39360263)
149. Endimiani A, Luzzaro F, Perilli M, et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 2004; 38: 243-51 (Pubitemid 38113033)
150. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extendedspectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12 (Pubitemid 32531482)
151. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39: 31-7 (Pubitemid 38879546)
152. Kang CI, Kim SH, Park WB, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004; 48: 4574-81
153. Castanheira M, Mendes RE, Woosley LN, et al. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09). J Antimicrob Chemother 2011; 66: 1409-11
154. Patel G, Bonomo RA. Status report on carbapenemases: challenges and prospects. Expert Rev Anti Infect Ther 2011; 9: 555-70
155. Souli M, Galani I, Antoniadou A, et al. An outbreak of infection due to beta-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010; 50: 364-73
156. Livermore DM, Warner M, Mushtaq S, et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011; 37: 415-9
157. Cezá rio RC, Duarte De Morais L, et al. Nosocomial outbreak by imipenem-resistant metallo-beta-lactamaseproducing Pseudomonas aeruginosa in an adult intensive care unit in a Brazilian teaching hospital. Enferm Infecc Microbiol Clin 2009; 27: 269-74
158. Van der Bij AK, Van Mansfeld R, Peirano G, et al. First outbreak of VIM-2 metallo-b-lactamase-producing Pseudomonas aeruginosa in the Netherlands: microbiology, epidemiology and clinical outcomes. Int J Antimicrob Agents 2011; 37: 513-8
159. Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43: 1379-82 (Pubitemid 29259329)
160. El Amari EB, Chamot E, Auckenthaler R, et al. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001; 33: 1859-64 (Pubitemid 33105125)
161. Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37: 154-60
162. Mastoraki A, Douka E, Kriaras I, et al. Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients. Surg Infect (Larchmt) 2008; 9: 153-60 (Pubitemid 351563818)
163. Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7: R78-83
164. Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008; 102: 407-12 (Pubitemid 351179979)
165. Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 2010; 65: 1019-27
166. Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006; 43 Suppl. 2: S89-94 (Pubitemid 44267146)
167. Michalopoulos AS, Tsiodras S, Rellos K, et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11: 115-21 (Pubitemid 40259694)
168. Nation RL, Li J. Optimizing use of colistin and polymyxin B in the critically ill. Semin Respir Crit Care Med 2007; 28: 604-14
169. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53: 3430-6
170. Li J, Milne RW, Nation RL, et al. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001; 761: 167-75 (Pubitemid 32817106)
171. Ló pez-Fabal F, Culebras E, Bonilla I, et al. In vitro activities of colistin combinations against Pseudomonas aeruginosa isolated from the intensive care unit [in Spanish]. Rev Esp Quimioter 2008; 21: 189-93
172. Lee SO, Kim NJ, Choi SH, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 2004; 48: 224-8 (Pubitemid 38040201)
173. Leroy O, d'Escrivan T, Devos P, et al. Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms. Infection 2005; 33: 129-35 (Pubitemid 40881103)
174. Baran G, Erbay A, Bodur H, et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis 2008; 12: 16-21
175. Pournaras S, Markogiannakis A, Ikonomidis A, et al. Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. J Antimicrob Chemother 2006; 57: 557-61 (Pubitemid 43240210)
176. Markogiannakis A, Fildisis G, Tsiplakou S, et al. Crosstransmission of multidrug-resistant Acinetobacter baumannii clonal strains causing episodes of sepsis in a trauma intensive care unit. Infect Control Hosp Epidemiol 2008; 29: 410-7 (Pubitemid 351589975)
177. Kohlenberg A, Brümmer S, Higgins PG, et al. Outbreak of carbapenem-resistant Acinetobacter baumannii carrying the carbapenemase OXA-23 in a German university medical centre. J Med Microbiol 2009; 58: 1499-507
178. Culebras E, Gonzá lez-Romo F, Head J, et al. Outbreak of Acinetobacter baumannii producing OXA-66 in a Spanish hospital: epidemiology and study of patient movements. Microb Drug Resist 2010; 16: 309-15
179. Garlantézec R, Bourigault C, Boles JM, et al. Investigation and management of an imipenem-resistant oxa-23 Acinetobacter baumannii outbreak in an intensive care unit. Med Mal Infect 2011 Aug; 41 (8): 430-6
180. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenemsusceptible VAP. Clin Infect Dis 2003; 36: 1111-8 (Pubitemid 36549630)
181. Levin AS, Barone AA, Penço J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrugresistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-11 (Pubitemid 29203530)
182. Reina R, Estenssoro E, Sá enz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005; 31: 1058-65 (Pubitemid 41125336)
183. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010; 65: 2645-9
184. Levin AS, Levy CE, Manrique AE, et al. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 2003; 21: 58-62 (Pubitemid 36043975)
185. Betrosian AP, Frantzeskaki F, Xanthaki A, et al. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008; 56: 432-6
186. Curcio D, Ferná ndez F, Vergara J, et al. Late onset ventilator-associate pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J Chemother 2009; 21: 58-62
187. Schafer JJ, Goff DA, Stevenson KB, et al. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007; 27: 980-7 (Pubitemid 46986684)
188. Montero A, Ariza J, Corbella X, et al. Antibiotic combinations for serious infections caused by carbapenemresistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004; 54: 1085-91 (Pubitemid 40136746)
189. Wareham DW, Bean DC. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob 2006; 5: 10
190. Motaouakkil S, Charra B, Hachimi A, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53: 274-8 (Pubitemid 44391062)
191. Principe L, D'Arezzo S, Capone A, et al. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob 2009; 8: 18
192. Sheng WH, Wang JT, Li SY, et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis 2011; 70: 380-6
193. Dizbay M, Tozlu DK, Cirak MY, et al. In vitro synergistic activity of tigecycline and colistin against XDRAcinetobacter baumannii. J Antibiot (Tokyo) 2010; 63: 51-3
194. Grau S, Alvarez-Lerma F. Pharmacoeconomics of infection in the intensive care unit. Rev Esp Quimioter 2008; 21 Suppl. 1: 26-34
195. Birminghant MC, Hassett JM, Schentag JJ, et al. Assessing antibacterial pharmacoeconomics in the intensive care unit. Pharmacoeconomics 1997; 12: 637-47 (Pubitemid 27520877)
196. Burchardi H, Schneider H. Economic aspects of severe sepsis. Pharmacoeconomics 2004; 22: 793-813
197. Chen Y-Y, Wang F-D, Liu C-Y, et al. Incidence rate and variable cost of nosocomial infections in different types of intensive care units. Infect Control Hosp Epidemiol 2009; 30: 39-46
198. Lawrence SJ, Puzniak LA, Shadel BN, et al. Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure. Infect Control Hosp Epidemiol 2007; 28: 123-30 (Pubitemid 46374151)
199. Shorr AF. Review of studies of the impact on gramnegative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 2009; 37: 1463-9
200. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42: S82-9 (Pubitemid 43054219)
201. Vandijck DM, Depaemelaere M, Labeau SO, et al. Daily cost of antimicrobial therapy in patients with intensive care unit-acquired, laboratory-confirmed bloodstream infection. Int J Antimicrob Agents 2008; 31: 161-5
202. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009; 49: 1175-84